Skip to main content

Cannabis stocks rally anew as $7 billion GW Pharma deal spurs interest in weed and its medical benefits

Cannabis stocks rallied anew on Wednesday, spurred on by news of a $7 billion deal for the first company to win U.S. regulatory approval for a cannabis-based drug, a move that's expected to boost investor interest in the plant and its medical benefits.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.